The cell cycle: A critical therapeutic target to prevent vascular proliferative disease

Canadian Journal of Cardiology

Volumn 22, Issue SUPPL. B, 2006, Pages 41B-55B

  Charron, Thierry ^a   Nili, Nafiseh ^a   Strauss, Bradley H ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Cell cycle; Drug eluting stent; Gene therapy; Pharmacology; Restenosis

Indexed keywords

6,7 DIMETHYL 2 PHENYLQUINOXALINE; ABT 578; AGL 2043; ALPHA CYANO 3 ETHOXY 4 HYDROXY 5 (PHENYLTHIOMETHYL)CINNAMAMIDE; ANTISENSE OLIGODEOXYNUCLEOTIDE; AVI 4126; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; DACTINOMYCIN; ESTRADIOL; EVEROLIMUS; FLAVOPIRIDOL; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; MYCOPHENOLIC ACID; OLIGODEOXYNUCLEOTIDE; PACLITAXEL; PERLECAN; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; RAPAMYCIN; RIBOZYME; SYNTHETIC DNA; TACROLIMUS; TRANSCRIPTION FACTOR E2F1; TYROSINE KINASE RECEPTOR; TYRPHOSTIN;

ANTIINFLAMMATORY ACTIVITY; ARTERY INTIMA PROLIFERATION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BINDING SITE; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG ELUTING STENT; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SOLUBILITY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; IN-STENT RESTENOSIS; INFLAMMATION; NONHUMAN; NONVIRAL GENE THERAPY; PATHOPHYSIOLOGY; PROTEIN PHOSPHORYLATION; REVIEW; THROMBOGENESIS; UNSPECIFIED SIDE EFFECT; VASCULAR SMOOTH MUSCLE;

EID: 33845701695     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0828-282x(06)70986-2     Document Type: Review

References (201)

1. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999;353:1547-57.
2. Mintz GS, Popma JJ, Pichard AD, et al. Arterial remodeling after coronary angioplasty: A serial intravascular ultrasound study. Circulation 1996;94:35-43.
3. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996;94:1247-54.
4. Wilensky RL, March KL, Gradus-Pizlo I, Sandusky G, Fineberg N, Hathaway DR. Vascular injury, repair, and restenosis after percutaneous transluminal angioplasty in the atherosclerotic rabbit. Circulation 1995;92:2995-3005.
5. Wong A, Chan C. Drug-eluting stents: The end of restenosis? Ann Acad Med Singapore 2004;33:423-31.
6. Topol EJ, Serruys PW. Frontiers in interventional cardiology. Circulation 1998;98:1802-20.
7. El-Omar MM, Dangas G, Iakovou I, Mehran R. Update on in-stent restenosis. Curr Interv Cardiol Rep 2001;3:296-305.
8. Mintz GS, Popma JJ, Hong MK, et al. Intravascular ultrasound to discern device-specific effects and mechanisms of restenosis. Am J Cardiol 1996;78:18-22.
9. Edelman ER, Rogers C. Pathobiologic responses to stenting. Am J Cardiol 1998;81:4E-6E.
10. Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model. J Am Coll Cardiol 1992;19:267-74.
11. Colombo A, De Scheerder I, Isner JM, Campbell R, Strauss BH. Restenosis: Multiple Strategies for Stent Drug Delivery. London: ReMEDICA, 2001:33-54.
12. Kipshidze N, Dangas G, Tsapenko M, et al. Role of the endothelium in modulating neointimal formation: Vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J Am Coll Cardiol 2004;44:733-9.
13. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-7.
14. Guo K, Andres V, Walsh K. Nitric oxide-induced downregulation of Cdk2 activity and cyclin A gene transcription in vascular smooth muscle cells. Circulation 1998;97:2066-72.
15. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: Still important, still much to learn. J Am Coll Cardiol 2004;44:1373-85.
16. Schwartz RS. Characteristics of an ideal stent based upon restenosis pathology. J Invasive Cardiol 1996;8:386-7.
17. Rogers C, Edelman ER, Simon DI. A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci USA 1998;95:10134-9.
18. Rectenwald JE, Moldawer LL, Huber TS, Seeger JM, Ozaki CK. Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation 2000;102:1697-702.
19. Wang X, Romanic AM, Yue TL, Feuerstein GZ, Ohlstein EH. Expression of interleukin-1 beta, interleukin-1 receptor, and interleukin-1 receptor antagonist mRNA in rat carotid artery after balloon angioplasty. Biochem Biophys Res Commun 2000;271:138-43.
20. Hojo Y, Ikeda U, Katsuki T, et al. Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis. Heart 2000;84:83-7.
21. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation 2002;105:2974-80.
22. Colombo A, De Scheerder I, Isner JM, Campbell R, Strauss BH. Restenosis: Multiple Strategies for Stent Drug Delivery. London: ReMEDICA, 2001:14.
23. Karas SP, Gravanis MB, Santoian EC, Robinson KA, Anderberg KA, King SB III. Coronary intimal proliferation after balloon injury and stenting in swine: An animal model of restenosis. J Am Coll Cardiol 1992;20:467-74.
24. Kornowski R, Hong MK, To FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: Contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998;31:224-30.
25. Yutani C, Ishibashi-Ueda H, Suzuki T, Kojima A. Histologic evidence of foreign body granulation tissue and de novo lesions in patients with coronary stent restenosis. Cardiology 1999;92:171-7.
26. Koster R, Vieluf D, Kiehn M, et al. Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet 2000;356:1895-7.
27. Shi Y, O'Brien JE, Fard A, Mannion JD, Wang D, Zalewski A. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation 1996;94:1655-64.
28. Scott NA, Cipolla GD, Ross CE, et al. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation 1996;93:2178-87.
29. Han CI, Campbell GR, Campbell JH. Circulating bone marrow cells can contribute to neointimal formation. J Vasc Res 2001;38:113-9.
30. Saiura A, Sata M, Hirata Y, Nagai R, Makuuchi M. Circulating smooth muscle progenitor cells contribute to atherosclerosis. Nat Med 2001;7:382-3.
31. Shimizu K, Sugiyama S, Aikawa M, et al. Host bone-marrow cells are a source of donor intimal smooth-muscle-like cells in murine aortic transplant arteriopathy. Nat Med 2001;7:738-41.
32. Graves JD, Krebs EG. Protein phosphorylation and signal transduction. Pharmacol Ther 1999;82:111-21.
33. Huang J, Kontos CD. Inhibition of vascular smooth muscle cell proliferation, migration, and survival by the tumor suppressor protein PTEN. Arterioscler Thromb Vasc Biol 2002;22:745-51.
34. Carter AJ. TOR of the cell cycle: Are there important implications for diabetics in the era of the drug-eluting stent? Catheter Cardiovasc Interv 2004;61:233-6.
35. Braun-Dullaeus RC, Mann MJ, Seay U, et al. Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler Thromb Vasc Biol 2001;21:1152-8.
36. Colombo A, De Scheerder I, Isner JM, Campbell R, Strauss BH, Restenosis: Multiple Strategies for Stent Drug Delivery. London: ReMEDICA, 2001:38.
37. Hunter T. Oncoprotein networks. Cell 1997;88:333-46.
38. Kelly K, Cochran BH, Stiles CD, Leder P. Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell 1983;35:603-10.
39. Hanson KD, Shichiri M, Follansbee MR, Sedivy JM. Effects of c-myc expression on cell cycle progression. Mol Cell Biol 1994;14:5748-55.
40. Phuchareon J, Tokuhisa T Deregulated c-Fos/AP-1 modulates expression of the cyclin and the cdk gene in splenic B cells stimulated with lipopolysaccharide. Cancer Lett 1995;92:203-8.
41. Daksis JI, Lu RY, Facchini LM, Marhin WW, Penn LJ. Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene 1994;9:3635-45.
42. Steiner P, Philipp A, Lukas J, et al. Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes. EMBO J 1995;14:4814-26.
43. Liu JJ, Chao JR, Jiang MC, Ng SY, Yen JJ, Yang-Yen HF. Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells. Mol Cell Biol 1995;15:3654-63.
44. Dobrowolski S, Harter M, Stacey DW. Cellular ras activity is required for passage through multiple points of the G0/G1 phase in BALB/c 3T3 cells. Mol Cell Biol 1994;14:5441-9.
45. Leone G, DeGregori J, Sears R, Jakoi L, Nevins JR. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 1997;387:422-6.
46. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995;9:1149-63.
47. Colombo A, De Scheerder I, Isner JM, Campbell R, Strauss BH. Restenosis: Multiple Strategies for Stent Drug Delivery. London: ReMEDICA, 2001:35.
48. Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression: New therapeutic target for vascular proliferative disease. Circulation 1998;98:82-9.
49. Weir L, Chen D, Pastore C, Isner JM, Walsh K. Expression of gax, a growth arrest homeobox gene, is rapidly down-regulated in the rat carotid artery during the proliferative response to balloon injury. J Biol Chem 1995;270:5457-61.
50. Gorski DH, LePage DF, Patel CV, Copeland NG, Jenkins NA, Walsh K. Molecular cloning of a diverged homeobox gene that is rapidly down-regulated during the G0/G1 transition in vascular smooth muscle cells. Mol Cell Biol 1993;13:3722-33.
51. Sriram V, Patterson C. Cell cycle in vasculoproliferative diseases: Potential interventions and routes of delivery. Circulation 2001;103:2414-9.
52. Fisher RP, Morgan DO. A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell 1994;78:713-24.
53. Jeffrey PD, Russo AA, Polyak K, et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 1995;376:313-20.
54. Paulovich AG, Hartwell LH. A checkpoint regulates the rate of progression through S phase in S. cerevisiae in response to DNA damage. Cell 1995;82:841-7.
55. Evans T, Rosenthal ET, Youngblom J, Distel D, Hunt T Cyclin: A protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell 1983;33:389-96.
56. Pines J. Cyclins: Wheels within wheels. Cell Growth Differ 1991;2:305-10.
57. Sherr CJ. G1 phase progression: Cycling on cue. Cell 1994;79:551-5.
58. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003;36:131-49.
59. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 1995;15:2612-24.
60. Girard F, Strausfeld U, Fernandez A, Lamb NJ. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 1991;67:1169-79.
61. Walker DH, Mallet JL. Role for cyclin A in the dependence of mitosis on completion of DNA replication. Nature 1991;354:314-7.
62. King RW, Jackson PK, Kirschner MW. Mitosis in transition. Cell 1994;79:563-71.
63. Arellano M, Moreno S. Regulation of CDK/cyclin complexes during the cell cycle. Int J Biochem Cell Biol 1997;29:559-73.
64. Carnero A, Hannon GJ. The INK4 family of CDK inhibitors. Curr Top Microbiol Immunol 1998;227:43-55.
65. Hengst L, Reed SI. Inhibitors of the Cip/Kip family. Curr Top Microbiol Immunol 1998;227:25-41.
66. Swanton C. Cell-cycle targeted therapies. Lancet Oncol 2004;5:27-36.
67. Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 1994;371:257-61.
68. Reynisdottir I, Polyak K, Iavarone A, Massague J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev 1995;9:1831-45.
69. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30.
70. DeGregori J, Kowalik T, Nevins JR. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol Cell Biol 1995;15:4215-24.
71. Stillman B. Smart machines at the DNA replication fork. Cell 1994;78:725-8.
72. Montagnoli A, Fiore F, Eytan E, et al. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 1999;13:1181-9.
73. Voitenleitner C, Fanning E, Nasheuer HP. Phosphorylation of DNA polymerase alpha-primase by cyclin A-dependent kinases regulates initiation of DNA replication in vitro. Oncogene 1997;14:1611-5.
74. Hartwell LH, Weinert TA. Checkpoints: Controls that ensure the order of cell cycle events. Science 1989;246:629-34.
75. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
76. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR. The p53 network. J Biol Chem 1998;273:1-4.
77. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994;369:574-8.
78. Gottlieb TM, Oren M. p53 and apoptosis. Semin Cancer Biol 1998;8:359-68.
79. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-9.
80. Galaktionov K, Chen X, Beach D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 1996;382:511-7.
81. Born TL, Frost JA, Schonthal A, Prendergast GC, Feramisco JR. c-Myc cooperates with activated Ras to induce the cdc2 promoter. Mol Cell Biol 1994;14:5710-8.
82. Ku DH, Wen SC, Engelhard A, et al. c-myb transactivates cdc2 expression via Myb binding sites in the 5′-flanking region of the human cdc2 gene. J Biol Chem 1993;268:2255-9.
83. Lew DJ, Kornbluth S. Regulatory roles of cyclin dependent kinase phosphorylation in cell cycle control. Curr Opin Cell Biol 1996;8:795-804.
84. Serruys PW, Foley DE Jackson G, et al. A randomized, placebo controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 1999;20:58-69.
85. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;287:3215-22.
86. Serruys PW, Rutsch W, Heyndrickx GR, et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restencisis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT). Circulation 1991;84:1568-80.
87. Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: Final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol 1995;25:362-9.
88. Meurice T, Bauters C, Hermant X, et al. Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): A randomised, double-blind, placebo-controlled trial. Lancet 2001;357:1321-4.
89. Emanuelsson H, Beatt KJ, Bagger JP, et al. Long-term effects of angiopeptin treatment in coronary angioplasty. Reduction of clinical events but not angiographic restenosis. European Angiopeptin Study Group. Circulation 1995;91:1689-96.
90. Galassi AR, Tamburino C, Nicosia A, et al. A randomized comparison of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, versus aspirin in prevention of angiographic restenosis after coronary artery Palmaz-Schatz stent implantation. Catheter Cardiovasc Interv 1999;46:162-8.
91. Serruys PW, Foley DR Pieper M, Kleijne JA, de Feyter PJ. The TRAPIST Study. A multicentre randomized placebo controlled clinical trial of trapidil for prevention of restenosis after coronary stenting, measured by 3-D intravascular ultrasound. Eur Heart J 2001;22:1938-47.
92. Holmes DR Jr, Savage M, LaBlanche JM, et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2002;106:1243-50.
93. Lee CW, Chae JK, Lim HY, et al. Prospective randomized trial of corticosteroids for the prevention of restenosis after intracoronary stent implantation. Am Heart J 1999;138:60-3.
94. Bailey S. Local drug delivery during percutaneous coronary intervention. Curr Interv Cardiol Rep 2000;2:349-57.
95. Zohlnhofer D, Klein CA, Richter T, et al. Gene expression profiling of human stent-induced neointima by cDNA array analysis of microscopic specimens retrieved by helix cutter atherectomy: Detection of FK506-binding protein 12 upregulation. Circulation 2001;103:1396-402.
96. Abraham RT. Mammalian target of rapamycin: Immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol 1998;10:330-6.
97. Dennis PB, Fumagalli S, Thomas G. Target of rapamycin (TOR): Balancing the opposing forces of protein synthesis and degradation. Curr Opin Genet Dev 1999;9:49-54.
98. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995;76:412-7.
99. Luo Y, Marx SO, Kiyokawa H, Koff A, Massague J, Marks AR. Rapamycin resistance tied to defective regulation of p27Kip1. Mol Cell Biol 1996;16:6744-51.
100. Brunn GJ, Hudson CC, Sekulic A, et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 1997;277:99-101.
101. Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA 1998;95:1432-7.
102. Woods TC, Marks AR. Drug-eluting stents. Annu Rev Med 2004;55:169-78.
103. Bonneton C, Sibarita JB, Thiery JP. Relationship between cell migration and cell cycle during the initiation of epithelial to fibroblastoid transition. Cell Motil Cytoskeleton 1999;43:288-95.
104. Sun J, Marx SO, Chen HJ, Poon M, Marks AR, Rabbani LE. Role for p27(Kip1) in vascular smooth muscle cell migration. Circulation 2001;103:2967-72.
105. Zohlnhofer D, Nuhrenberg TG, Neumann FJ, et al. Rapamycin effects transcriptional programs in smooth muscle cells controlling proliferative and inflammatory properties. Mol Pharmacol 2004;65:880-9.
106. Knies UE, Behrensdorf HA, Mitchell CA, et al. Regulation of endothelial monocyte-activating polypeptide II release by apoptosis. Proc Natl Acad Sci USA 1998;95:12322-7.
107. Daemen MA, van't Veer C, Denecker G, et al. Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J Clin Invest 1999;104:541-9.
108. Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999;99:2164-70.
109. Rodriguez AE, Alemparte MR, Vigo CF, et al. Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stent therapy: Argentina Single-Center Study (ORAR Trial). J Invasive Cardiol 2003;15:581-4.
110. Waksman R, Ajani AE, Pichard AD, et al. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: The Oral Rapamune to Inhibit Restenosis (ORBIT) study. J Am Coll Cardiol 2004;44:1386-92.
111. Brara PS, Moussavian M, Grise MA, et al. Pilot trial of oral rapamycin for recalcitrant restenosis. Circulation 2003;107:1722-4.
112. Hausleiter J, Kastrati A, Mehilli J, et al. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation 2004;110:790-5.
113. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004;109:190-5.
114. Wieneke H, Dirsch O, Sawitowski T, et al. Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. Catheter Cardiovasc Interv 2003;60:399-407.
115. Grube E, Buellesfeld L. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents. Herz 2004;29:162-6.
116. Honda H, Kar S, Honda T, et al. Everolimus eluting stents significantly inhibit neointimal hyperplasia in an experimental pig coronary model. Am J Cardiol 2002;90(Suppl 6A):73H.
117. Honda T, Kar S, Honda H, et al. Stent-based delivery of everolimus leads to complete vessel wall healing without toxicity in a 90-day porcine model. Am J Cardiol 2002;90(Suppl 6A):80H.
118. Buellesfeld L, Grube E. ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts? Herz 2004;29:167-70.
119. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation 1997;64:36-42.
120. Grube E, Buellesfeld L. Everolimus for stent-based intracoronary applications. Rev Cardiovasc Med 2004;5(Suppl 2):S3-8.
121. Matter MC, Wnendt S, Kurz DJ, et al. Tacrolimus, but not sirolimus targets human vascular smooth muscle cells, but spares endothelial cells - implications for drug-eluting stents. Eur Heart J 2002;4(Suppl):143. (Abst)
122. Mohacsi PJ, Tuller D, Hulliger B, Wijngaard PL. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 1997;16:484-92.
123. Morris RE. Mechanisms of action of new immunosuppressive drugs. Kidney Int Suppl 1996;53:S26-38.
124. Sakuma S, Higashi Y, Sato N, et al. Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids). Int Immunopharmacol 2001;1:1219-26.
125. Aghdasi B, Ye K, Resnick A, et al. FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle. Proc Natl Acad Sci USA 2001;98:2425-30.
126. Brunner T, Yoo NJ, LaFace D, Ware CF, Green DR. Activation-induced cell death in murine T cell hybridomas. Differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506. Int Immunol 1996;8:1017-26.
127. 1 in mammalian lymphoid as well as nonlymphoid cells. Transplantation 1999;67:614-9.
128. Grube E. Final tacrolimus outcomes in native coronaries and saphenous vein grafts: PRESENT & EVIDENT American College of Cardiology Meeting. Chicago, March 30 to April 2, 2003.
129. Meredith IT. ENDEAVOR I: Safety and efficacy of the ABT-578-coated Endeavor stent - 12-month follow-up. EuroPCR. Paris, May 25 to 28, 2004.
130. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993;90:9552-6.
131. Giannakakou P, Robey R, Fojo T, Blagosklonny MV. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: Molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 2001;20:3806-13.
132. Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-45.
133. Lansky AJ, Costa RA, Mintz GS, et al. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: Angiogtaphic follow-up of the DELIVER clinical trial. Circulation 2004;109:1948-54.
134. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-94.
135. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
136. Moses JW, Kipshidze N, Leon MB. Perspectives of drug-eluting stents: The next revolution. Am J Cardiovasc Drugs 2002;2:163-72.
137. Serruys PW, Ormiston JA, Sianos G, et al. Actinomycin-eluting stent for coronary revascularization: A randomized feasibility and safety study: The ACTION trial. J Am Coll Cardiol 2004;44:1363-7.
138. Abizaid AC. Novel studies with drug-eluting stents: New drug-eluting stent trials: EASTER, IMPACT PISCES, BioRest, and more. Transcatheter Cardiovascular Therapeutics Annual Scientific Symposia. Washington, September 15 to 19, 2003.
139. Sudhir K, Chou TM, Mullen WL, et al. Mechanisms of estrogen-induced vasodilation: In vivo studies in canine coronary conductance and resistance arteries. J Am Coll Cardiol 1995;26:807-14.
140. White CR, Shelton J, Chen SJ, et al. Estrogen restores endothelial cell function in an experimental model of vascular injury. Circulation 1997;96:1624-30.
141. New G, Moses JW, Roubin GS, et al. Estrogen-eluting, phosphorylcholine-coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model. Catheter Cardiovasc Interv 2002;57:266-71.
142. Chen SJ, Li H, Durand J, Oparil S, Chen YF. Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation 1996;93:577-84.
143. Geraldes P, Sirois MG, Tanguay JF. Specific contribution of estrogen receptors on mitogen-activated protein kinase pathways and vascular cell activation. Circ Res 2003;93:399-405.
144. Abizaid A, Albertal M, Costa MA, et al. First human experience with the 17-beta-estradiol-eluting stent: The Estrogen And Stents To Eliminate Restenosis (EASTER) trial. J Am Coll Cardiol 2004;43:1118-21.
145. Gray N, Detivaud L, Doerig C, Meijer L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr Med Chem 1999;6:859-75.
146. Jaschke B, Milz S, Vogeser M, et al. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury. FASEB J 2004;18:1285-7.
147. Ruef J, Meshel AS, Hu Z, et al. Flavopiridol inhibits smooth muscle cell proliferation in vitro and neointimal formation In vivo after carotid injury in the rat. Circulation 1999;100:659-65.
148. Iozzo RV, Cohen IR, Grassel S, Murdoch AD. The biology of perlecan: The multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J 1994;302:625-39.
149. Forsten KE, Courant NA, Nugent MA. Endothelial proteoglycans inhibit bFGF binding and mitogenesis. J Cell Physiol 1997;172:209-20.
150. Paka L, Goldberg IJ, Obunike JC, et al. Perlecan mediates the antiproliferative effect of apolipoprotein E on smooth muscle cells. An underlying mechanism for the modulation of smooth muscle cell growth? J Biol Chem 1999;274:36403-8.
151. Lundmark K, Tran PK, Kinsella MG, Clowes AW, Wight TN, Hedin U. Perlecan inhibits smooth muscle cell adhesion to fibronectin: Role of heparan sulfate. J Cell Physiol 2001;188:67-74.
152. Koyama N, Kinsella MG, Wight TN, Hedin U, Clowes AW. Heparan sulfate proteoglycans mediate a potent inhibitory signal for migration of vascular smooth muscle cells. Circ Res 1998;83:305-13.
153. Nugent MA, Nugent HM, Iozzo RV, Sanchack K, Edelman ER. Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhibition of intimal hyperplasia. Proc Natl Acad Sci USA 2000;97:6722-7.
154. Kojima T, Leone CW, Marchildon GA, Marcum JA, Rosenberg RD. Isolation and characterization of heparan sulfate proteoglycans produced by cloned rat microvascular endothelial cells. J Biol Chem 1992;267:4859-69.
155. Benitz WE, Kelley RT, Anderson CM, Lorant DE, Bernfield M. Endothelial heparan sulfate proteoglycan. I. Inhibitory effects on smooth muscle cell proliferation. Am J Respir Cell Mol Biol 1990;2:13-24.
156. Garl PJ, Wenzlau JM, Walker HA, Whitelock JM, Costell M, Weiser-Evans MC. Perlecan-induced suppression of smooth muscle cell proliferation is mediated through increased activity of the tumor suppressor PTEN. Circ Res 2004;94:175-83.
157. Sirois MG, Simons M, Edelman ER. Antisense oligonucleotide inhibition of PDGFR,beta receptor subunit expression directs suppression of intimal thickening. Circulation 1997;95:669-76.
158. Desfaits AC, Raymond J, Muizelaar JP. Growth factors stimulate neointimal cells in vitro and increase the thickness of the neointima formed at the neck of porcine aneurysms treated by embolization. Stroke 2000;31:498-507.
159. Ding H, Wang R, Marcel R, Fisher DZ. Adenovirus-mediated expression of a truncated PDGFbeta receptor inhibits thrombosis and neointima formation in an avian arterial injury model. Thromb Haemost 2001;86:914-22.
160. Buetow BS, Tappan KA, Crosby JR, Seifert RA, Bowen-Pope DF. Chimera analysis supports a predominant role of PDGFRbeta in promoting smooth-muscle cell chemotaxis after arterial injury. Am J Pathol 2003;163:979-84.
161. Gazit A, Yee K, Uecker A, et al. Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorg Med Chem 2003;11:2007-18.
162. Banai S, Gertz SD, Gavish L, et al. Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries. Cardiovasc Res 2004;64:165-71.
163. Banai S, Wolf Y, Golomb G, et al. PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. Circulation 1998;97:1960-9.
164. Fishbein I, Waltenberger J, Banai S, et al. Local delivery of platelet-derived growth factor receptor-specific tyrphostin inhibits neointimal formation in rats. Arterioscler Thromb Vasc Biol 2000;20:667-76.
165. Fishbein I, Chorny M, Banai S, et al. Formulation and delivery mode affect disposition and activity of tyrphostin-loaded nanoparticles in the rat carotid model. Arterioscler Thromb Vasc Biol 2001;21:1434-9.
166. Yamawaki T, Shimokawa H, Kozai T, et al. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol 1998;32:780-6.
167. Chang MW, Barr E, Seltzer J, et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995;267:518-22.
168. Chang MW, Barr E, Lu MM, Barton K, Leiden JM. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 1995;96:2260-8.
169. Chen D, Krasinski K, Sylvester A, Chen J, Nisen PD, Andres V. Downregulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor of neointima formation in the rat carotid artery. J Clin Invest 1997;99:2334-41.
170. Yang ZY, Simari RD, Perkins ND, et al. Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc Natl Acad Sci USA 1996;93:7905-10.
171. Yonemitsu Y, Kaneda Y, Tanaka S, et al. Transfer of wild-type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo. Circ Res 1998;82:147-56.
172. Yonemitsu Y, Kaneda Y, Hata Y, Nakashima Y, Sueishi K. Wild-type p53 gene transfer: A novel therapeutic strategy for neointimal hyperplasia after arterial injury. Ann N Y Acad Sci 1997;811:395-400.
173. Maillard L, Van Belle E, Smith RC, et al. Percutaneous delivery of the gax gene inhibits vessel stenosis in a rabbit model of balloon angioplasty. Cardiovasc Res 1997;35:536-46.
174. Perlman H, Luo Z, Krasinski K, et al. Adenovirus-mediated delivery of the Gax transcription factor to rat carotid arteries inhibits smooth muscle proliferation and induces apoptosis. Gene Ther 1999;6:758-63.
175. Maillard L, Van Belle E, Tio FO, et al. Effect of percutaneous adenovirus-mediated Gax gene delivery to the arterial wall in double-injured atheromatous stented rabbit iliac arteries. Gene Ther 2000;7:1353-61.
176. Morishita. R. Perspective in progress of cardiovascular gene therapy. J Pharmacol Sci 2004;95:1-8.
177. Morishita R, Gibbons GH, Ellison KE, et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993;90:8474-8.
178. Morishita R, Gibbons GH, Ellison KE, et al. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest 1994;93:1458-64.
179. Morishita R, Gibbons GH, Kaneda Y, Ogihara T, Dzau VJ. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: Enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene 1994;149:13-9.
180. Abe J, Zhou W, Taguchi J, et al. Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in tat carotid artery. Biochem Biophys Res Commun 1994;198:16-24.
181. Simons M, Edelman ER, DeKeyser JL, Langer R, Rosenberg RD. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 1992;359:67-70.
182. Simons M, Edelman ER, Rosenberg RD. Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model. J Clin Invest 1994;93:2351-6.
183. Shi Y, Fard A, Galeo A, et al. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation 1994;90:944-51.
184. Suzuki J, Isobe M, Morishita R, et al. Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide. Nat Med 1997;3:900-3.
185. Kutryk MJ, Foley DP, van den Brand M, et al. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: Results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J Am Coll Cardiol 2002;39:281-7.
186. Kipshidze NN, Kim HS, Iversen P, et al. Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model. J Am Coll Cardiol 2002;39:1686-91.
187. Mann MJ, Gibbons GH, Kernoff RS, et al. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci USA 1995;92:4502-6.
188. Kipshidze N, Overlie P, Dunlap T et al. First human experience with local delivery of novel antisense AVI-4126 with infiltrator catheter in de novo native and restenotic coronary arteries: Six-month clinical and angiographic follow-up from AVAIL study. Circulation 2004;110(Suppl 3):757. (Abst)
189. Kipshidze NN, Iversen P, Kim HS, et al. Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model. Catheter Cardiovasc Interv 2004;61:518-27.
190. Frimerman A, Welch PJ, Jin X, et al. Chimeric DNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduces stent-induced stenosis in a porcine coronary model. Circulation 1999;99:697-703.
191. Macejak DG, Lin H, Webb S, et al. Adenovirus-mediated expression of a ribozyme to c-myb mRNA inhibits smooth muscle cell proliferation and neointima formation in vivo. J Virol 1999;73:7745-51.
192. Morishita. R, Gibbons GH, Horiuchi M, et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995;92:5855-9.
193. Mann MJ, Whittemore AD, Donaldson MC, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial. Lancet 1999;354:1493-8.
194. Mann MJ, Conte MS. Transcription factor decoys for the prevention of vein bypass graft failure. Am J Cardiovasc Drugs 2003;3:79-85.
195. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
196. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
197. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: Double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-9.
198. Schampaert E, Cohen EA, Schluter M, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-5.
199. Grube E, Sonoda S, Ikeno F, et al. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 2004;109:2168-71.
200. Grube E, Costa R, Mehran R. Everolimus-eluting stents for the prevention of restenosis: Results of the FUTURE II trial. J Am Coll Cardiol 2004;43(Suppl A):86A.
201. Serruys PW. SPIRIT FIRST: Everolimus-cluting stent looks promising at six months. Transcatheter Cardiovascular Therapeutics Annual Scientific Symposia. Washington, September 27 to October 1, 2004.